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2710for many patients with CTOs). Although the mortality
curves for partial and complete revascularization
brieﬂy overlap, there is a signiﬁcant statistical dif-
ference between them. Therefore, the statement that
the greatest difference was observed among patients
with complete revascularization is correct.
In response to Dr. Antoniucci and colleagues, the
vast majority of the interventions (>95%) were carried
out for treatment of angina in stable patients. Patient
management was according to the standard practice of
the clinicians in each institution, and therefore pre-
procedural myocardial viability assessment and type
of stent used varied. They state that there is a “strong
impact on survival of. drug-eluting stents after CTO
PCI” but then go on to add that “patients with a CTO
and single-vessel disease have a very low mortality
rate and it is likely that the outcome cannot be
improved by successful PCI.” These statements seem
at odds with each other, which is not helped by the
ﬁnal assertion that there is a “strong rationale for
revascularization of a CTO vessel supplying a large
amount of viable myocardium.” Which is correct?
Although the European Chronic Total Occlusion Study
is indeed recruiting slowly, we are hopeful that with
long enough follow-up, useful data will emerge.
We fully agree with Dr. Hiser’s excellent letter and
the statement that “one cannot imply beneﬁt of
revascularization because those with successful
interventions do better than those with failed in-
terventions.” We drew attention to this brieﬂy in the
second paragraph of the discussion; it is indeed
possible that disease burden dictates the outcome
rather than success or failure of the procedure. This is
why we have stated the differences observed without
implying causation. This is also why randomized tri-
als are required in this area and why the EuroCTO
(European Chronic Total Occlusion) trial is important.*Sudhakar George, MD
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Time to Reassess the Speciﬁc Impact of Drug
Therapy in Coronary Heart Disease PatientsRecently b-blocker drugs have been accepted as the
standard of care for angina and coronary heart dis-
ease, especially when patients have had myocardial
infarction. However, the ﬁnding by Andersson et al.
(1) on b-blocker effects only in recent myocardial in-
farcts opens an interesting question in cardiovascular
pharmacology, in which 2 major points deserve
consideration.
First, the references in Andersson et al. (1) demon-
strated that treatment with b-blockers had no statis-
tically signiﬁcant impact on mortality compared to
placebo or other active comparator in clinical trials for
patients with stable angina (Ref. 7 in the Andersson
et al. article), and were not associated with lower
incidence of cardiovascular events in patients with
previous history of myocardial infarction (MI), among
patients with coronary heart disease (CHD) but no
history of MI, or among patients with risk factors for
atherosclerotic disease only (44,708 subjects) (Ref. 8
in the Andersson et al. article).
With further reﬁnement, the AVANCE Register
study (2,024 angina patients in stable condition, 419
cardiologists) (2) found that despite b-blockers (75%
to 79%), statins (90% to 93%), antiplatelets (95% to
97%), nitrates (61% to 100%), and calcium antagonists
(44%), a higher proportion of patients had angina
(49.3%), including those with revascularization (66%)
who had angina (59%). In addition, patients per-
ceived their condition as being more serious than
their physicians, independently of symptom in-
tensity, suggesting that the optimal target for quality
of life or angina has not been currently achieved.
FIGURE 1 Myocardial Capillary Net
Electron microscopy views at the myocardial capillary net. ATP ¼ adenosine triphosphate.
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2711Unfortunately, no information is available on the
number of patients who remain with ischemic elec-
trocardiogram (ECG) with or without angina, in any
speciﬁc groups of drug treatment, including coronary
interventions.
As mentioned previously, a second point arises
when coronary intervention or surgery is required to
enhance coronary blood perfusion in CHD patients.
However, the incontrovertible fact is that O2 supply is
only possible at the capillary bed, involving the most
critical role of erythrocyte K-dependent adenosine
triphosphate (ATP) synthesis and releases for in-
stantaneous H/K and O2/CO2 exchanges in myocar-
dial capillary bed (Figure 1). In fact, because
intracoronary administration of nitroglycerin fails to
relieve angina induced by atrial pacing, which rapidly
reversed by the intravenous or sublingual doses (3), it
is reasonable to assume that the enhanced hemoglo-
bin oxygen binding in the lung capillary bed could be
a required step for the antianginal effects of nitrates
or any other drug treatments.
This hypothesis is supported by the in vitro
oxygen-K binding by human oxyhemoglobin discov-
ery in our laboratory (4), along with the evidence that
the increased erythrocyte-K content by Amiloride
HCl dihydrate reverses angina and ST-T alteration
of ischemia in CHD patients (5). Certainly, this
K-dependent ATP function should be preserved in the
presence of an inherited defect in red-blood-cell-
potassium (RBC-K) uptake, or drugs affecting RBC-K
transport including loop diuretic agents, propranolol
or gastric H-K ions ATPase pump inhibitors.
Finally, although the ECG alterations of ischemia in
resting ECG, or induced by pacing and treadmill tests
are landmark evidence of CHD, the simple fact is that
we have no deﬁnite information on drug treatment or
coronary interventions that completely reverse ECG
alterations and angina. Because extensive cardiovas-
cular studies have documented that baseline ECG
abnormalities or new and persistent ECG alterations
are associated with increased cardiovascular events,
it is clear that it is time to reassess the impact of drug
treatment, coronary intervention, or coronary proce-
dure in patients with CHD.
Electron microscopy view at the myocardial capil-
lary net, in which diameters and blood ﬂow is tightly
controlled by a RBC-K dependent enzyme (pyruvate
kinase activity) required for ATP synthesis and ATP
release in the presence of low pH or PO2, is the most
powerful regulator of capillary vasodilation and blood
ﬂow in healthy and ischemic tissues.
However, an anatomical aspect is well evident: the
larger RBC diameter (7  0.5 mm) versus most micro-
vascular beds (3.5-5.0 mm). However, despite thesenarrower capillary diameters, the ﬂow velocity of
these cells in healthy subject is 300–400 m/sec, criti-
cally dependent of RBC-K pyruvate kinase activity.
Therefore, impaired vasodilation and longer transit
time of RBC, instead of increased vascular resistances
in conductive arteries, appears to be the major factor
involved on the pathogenesis of hypertension and
CHD, supporting a novel paradigm in the manage-
ment and treatment of CHD and other cardiovascular
diseases.*Antonio Delgado-Almeida, MD
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Time to Reassess the Speciﬁc Impact of Drug Therapy in
Coronary Heart Disease PatientsWe thank Dr. Delgado-Almeida for his interest in our
paper (1).
We agree that control of angina and improvement
of quality of life are important goals of treatment, but
we do not have data on the effect of beta-blocker
treatment on these patient-related outcomes. It is
important to note that treatments may relieve angina
symptoms with no effect on mortality (and vice versa)
and that relief of angina remains an important indi-
cation for treatment.
Dr. Delgado-Aleida’s comments about the role of
the capillary bed, oxygen binding, red blood celldeformation, and vasodilation are interesting and
deserve to be investigated. Irrespective of possible
mechanisms of action, we need reliable empirical
evidence about actual clinical outcomes to inform
treatment decisions.*Mark A. Hlatky, MD
Charlotte Andersson, MD, PhD
Tara I. Chang, MD, MS
Dhruv Kazi, MD, MS
Matthew D. Solomon, MD, PhD
Alan S. Go, MD
*Department of Health Research and Policy
Stanford University
HRP Redwood Building, Room 150
Stanford, California 94305
E-mail: hlatky@stanford.edu
http://dx.doi.org/10.1016/j.jacc.2014.10.003
Please note: Philippe Gabriel Steg, MD, served as the Guest Editor for this
Letter.R EF E RENCE
1. Andersson C, Shilane D, Go AS, et al. Beta-blocker therapy and cardiac
events among patients with newly diagnosed coronary heart disease. J Am
Coll Cardiol 2014;64:247–52.
